AtheroMed

AtheroMed develops innovative medical devices focused on enhancing cardiovascular health through advanced technologies that treat atherosclerotic disease, aiming to improve arterial function and patient outcomes. AtheroMed is a medical device company specializing in solutions for cardiovascular health. The company was acquired by Volcano Corporation in May 2014 for USD 115 mn. They are headquartered in Menlo Park, California, US.

The founder's history is not available. AtheroMed Inc. specializes in the development of innovative medical devices aimed at improving cardiovascular health. Their core product offering includes advanced technologies designed for the treatment of atherosclerotic disease, specifically focusing on improving arterial health and reducing the risk of major cardiovascular events.

These products are engineered to enhance the precision of arterial interventions, thereby addressing critical end-use cases such as plaque stabilization and prevention of artery blockages. The company's solutions are utilized primarily by healthcare professionals in hospital and outpatient settings, targeting cardiologists and vascular surgeons who serve patients with cardiovascular conditions. Atheromed's products are marketed in key geographical regions, including North America and select markets in Europe, ensuring access to a broad range of end users who require effective cardiovascular treatments. Atheromed Inc.

generates revenue through a direct sales model, primarily engaging with hospitals and medical facilities that implement its advanced medical devices. The transaction structure typically involves direct purchases by healthcare providers, where products are sold either outright or through financing arrangements that may include subscription-like services for ongoing support and updates. Specific pricing plans are established based on the product offerings, with flagship devices commanding premium pricing due to their advanced technology and clinical efficacy. The firm’s revenue is bolstered by strategic partnerships with healthcare institutions that facilitate the integration of their devices into treatment protocols, thereby enhancing patient outcomes and encouraging repeat business from satisfied customers.

AtheroMed is focused on expanding its product line with new medical devices aimed at improving cardiovascular treatments, with potential releases planned for the upcoming years. The company is also looking to expand its market reach in Europe and Asia by 2015. The recent acquisition by Volcano Corporation for USD 115 mn will likely support these initiatives by providing additional capital for research and development efforts, as well as facilitating entry into new markets.